Back to Treatments

Treatment

Rituximab with GMALL-B-ALL-BFM

1
Conditions
35
Trials
3,500
Participants
25%
Average Safety

Condition Evidence

Burkitt lymphoma

35 trials · 3,500 participants

90% effectiveness · 25% safety
Rituximab with GMALL-B-ALL-BFM | DFDA